Mycoprotein for Health & Longevity - Quick Reference Sheet

Mycoprotein for Health & Longevity

Created on 09/22/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

Replacing meat and fish with this fungal food lowers blood cholesterol, flattens the insulin rise after a meal, curbs intake at the next meal, and builds muscle after strength training as well as milk protein. Fungal cells raise uric acid; digestive upset and mould-linked allergic reactions occur. Trials are small and short, with no illness or lifespan data. (Full Review)

Protocol

Standard substitution protocol
240 g daily
Mycoprotein-containing product replacing red and processed meat, for at least two weeks
Acute muscle-support bolus
70 g
Roughly 31.5 g protein and 2.5 g leucine, within about an hour after strength training
Single versus split dosing
Split across two meals
Spreads the fibre and nucleotide load and matches the four-hour amino acid window; lunch and dinner in the substitution trials
Time to effect
Cholesterol
2–4 weeks
Complete by eight weeks in the longest lipid trial
Muscle adaptation
10 weeks
Lean mass gain matched an omnivorous diet over the training block
Satiety and insulin
First meal
Both measured in single-meal trials, against an equal-energy chicken meal

Benefits

Contraindications
  • Confirmed IgE-mediated allergy to mycoprotein or Fusarium species
  • Prior anaphylaxis or angioedema after any mycoprotein-containing product
  • Active gout (serum urate above 360 µmol/L, or two or more flares in the preceding 12 months), for nucleotide-rich preparations
  • Advanced chronic kidney disease (eGFR below 30 mL/min/1.73 m², stage 4 or 5)
  • Egg or milk allergy, for the non-vegan formulations
  • Coeliac disease or wheat allergy, for the formulations that contain wheat gluten
Key Interactions
  • Urate-lowering therapy (allopurinol, febuxostat)
  • Urate-raising prescription drugs (hydrochlorothiazide, furosemide, low-dose ciclosporin)
  • Narrow-absorption oral medications (levothyroxine, tetracycline antibiotics)
  • Low-dose aspirin (75–100 mg daily) and niacin
  • Cholesterol-lowering supplements (psyllium, beta-glucan, plant sterols, berberine)
  • Guar gum and other viscous fibres
  • Iron and zinc supplements
  • Glucagon-like peptide-1 (GLP-1) receptor agonists

Risk & Side Effects

  • High: Elevated serum uric acid
  • Medium: Gastrointestinal intolerance; immediate allergic reaction
  • Low: Nutrient gaps from displacing animal protein; no reliable triglyceride benefit; processed product matrix offsetting the ingredient
  • Speculative: Mycotoxin carry-over

Monitoring

Marker Target Why
LDL cholesterol < 2.6 mmol/L (100 mg/dL); < 1.8 mmol/L with existing artery disease Primary benefit endpoint
Total cholesterol < 5.0 mmol/L (193 mg/dL) The endpoint pooled in meta-analysis
Apolipoprotein B < 0.80 g/L; < 0.65 g/L for aggressive targets Particle count tracks risk better than cholesterol mass
Serum uric acid 210–330 µmol/L (3.5–5.5 mg/dL) Primary risk endpoint from the nucleotide load
Estimated glomerular filtration rate > 90 mL/min/1.73 m² Sets urate clearance capacity and the safe nucleotide ceiling
HbA1c < 5.4% (36 mmol/mol) Tracks whether the postprandial insulin benefit translates
Fasting insulin < 36 pmol/L (5 µIU/mL) The marker mycoprotein moves most consistently
Vitamin B12 > 400 pmol/L (540 pg/mL) Mycoprotein supplies none; deficiency is the main displacement risk
Ferritin 50–150 µg/L Detects falling iron stores when haem iron is displaced
High-sensitivity C-reactive protein < 1.0 mg/L General inflammation marker; the speculative anti-inflammatory claim would show here

Cadence: Serum uric acid at 4 weeks; lipid panel and apolipoprotein B at 8–12 weeks; then both every 6–12 months once stable. Vitamin B12 and ferritin at 6 months, then annually.

Qualitative Assessment

  • Gastrointestinal comfort in the 1–4 hours after a mycoprotein meal, which is when intolerance reactions cluster
  • Any skin flushing, itching, lip or throat swelling within the first hour, the window in which 45.8% of allergic reactions began
  • Fullness and time to next hunger, the subjective counterpart of the measured reduction in energy intake
  • Joint pain or big-toe tenderness, the earliest signal that rising urate has reached flare territory
  • Training recovery and session quality across an 8–10 week block, the practical readout of the muscle findings
  • Energy stability across the afternoon, which tracks the flatter insulin response